Pharmacokinetics of apixaban in patients with short bowel syndrome requiring long-term parenteral nutrition.
Apixaban is a common blood-thinning tablet used to prevent and treat dangerous blood clots. It is swallowed and absorbed through the gut. However, people with short bowel syndrome have lost a large part of their small intestine and rely on liquid nutrition directly into their veins, known as parenteral nutrition. Because their digestive system is much shorter, their bodies may not absorb tablets in the usual way. This study compares how two different single doses of apixaban (2.5 mg and 5 mg) are absorbed by people with short bowel syndrome compared to people with a healthy gut. By measuring peak levels of the medicine in the blood, doctors hope to understand whether standard doses are safe and effective for people with this condition, or if treatment plans need to be adjusted in the future.
At a glance
What is this study about?
Short bowel syndrome is a condition where a person is missing a large section of their small intestine, often due to surgery or illness. Because the gut is much shorter than usual, it cannot absorb enough food, fluids, or nutrients. Many people with this condition rely on long-term intravenous feeding (parenteral nutrition) to stay healthy. This reduced gut length can also make it difficult for the body to properly absorb medicines that are taken by mouth.
Apixaban is a widely used tablet that helps stop blood clots from forming. Doctors often need to prescribe blood thinners, but it is currently unclear how well apixaban gets into the bloodstream when someone has short bowel syndrome. If too little medicine is absorbed, it might not protect against blood clots. If too much builds up, it could raise the risk of bleeding.
In this study, researchers want to measure exactly how much apixaban enters the blood after taking a single tablet at two different strengths (2.5 mg and 5 mg). They will compare results from people with short bowel syndrome to people without the condition. This will help doctors learn whether apixaban can be used reliably for these patients or if different dosing approaches are needed.
Key takeaways
- The trial tests how well the blood thinner apixaban is absorbed in people with short bowel syndrome.
- Participants take single doses of 2.5 mg and 5 mg on separate test days.
- Multiple blood tests are taken to measure the peak levels of medicine in the bloodstream.
- Open to adults aged 18 and older who need long-term intravenous feeding, as well as comparison volunteers.
- Taking part is voluntary and will not disrupt your regular nutritional care.
Who may be eligible?
This study is open to adults aged 18 and older. The researchers are looking for people who have short bowel syndrome and require long-term intravenous feeding (parenteral nutrition) to meet their nutritional needs. They may also look at some patients who receive specific gut treatments such as teduglutide.
To see how results compare, the study also includes a comparison group of adults who do not have short bowel syndrome and have a normal digestive system.
People might not be able to take part if they have active, serious bleeding problems, severe kidney or liver disease, or if they are taking other medicines that cannot be safely mixed with apixaban. The study team will review each person's full medical history and current medications before confirming if they can join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with short bowel syndrome.
- I currently rely on long-term intravenous nutrition (parenteral nutrition).
- I do not have a current medical condition that causes serious bleeding.
- I am willing to attend clinic visits for blood tests after taking a study tablet.
What does participation involve?
Taking part in this study involves attending a hospital or clinic to take single doses of the study medicine under medical supervision. Participants will take a low dose (2.5 mg) and a standard dose (5 mg) of apixaban on separate occasions.
During each visit, the research team will take several blood samples over a set number of hours to track the medicine levels as it is absorbed and cleared by the body. Staff will also check vital signs, such as blood pressure and heart rate, and ask about any side effects. Because this trial looks at single doses rather than long-term daily treatment, the overall time commitment usually involves a few appointments spread over a short period. The study team will explain the exact schedule before you decide to take part.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is apixaban?
Apixaban is an anticoagulant, or blood-thinning medicine. It helps prevent blood clots from forming in your blood vessels.
Will I have to stop my regular nutrition support?
No, your essential nutritional support and regular medical care will continue as advised by your healthcare team.
Does taking part mean I must stay on this medicine permanently?
No. This study only tests single doses to measure blood levels. It is not an ongoing daily treatment.
Will having blood samples taken hurt?
You may feel a small scratch when the needle is inserted, and you might get a mild bruise, but the team will take care to keep you comfortable.
Can I leave the study if I change my mind?
Yes. Joining is completely voluntary, and you can withdraw at any point without it affecting your ongoing treatment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.